SS
FLXN

Steve Schonfeld’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Steve Schonfeld’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-18,625
Closed -$154K – 2653
2021
Q2 		$154K Buy
+18,625
New +$158K ﹤0.01% 1734

Other funds holding FLXN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steve Schonfeld's FLXN Position: Q3 2021 in Review

Steve Schonfeld sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2021, closing a stake of 18,625 shares — an estimated $154K sold.

Steve Schonfeld first reported a position in FLXN in Q2 2021 and held it in 1 quarter. The position peaked at $154K in Q2 2021. 145 funds tracked by Wall St. Rank hold FLXN as of Q3 2021.

  • Steve Schonfeld reported no remaining Flexion Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Steve Schonfeld sold 18,625 Flexion Therapeutics, Inc. shares in Q3 2021, an estimated $154K.
  • Steve Schonfeld first reported a position in Flexion Therapeutics, Inc. in Q2 2021 and held it in 1 quarter.
  • Steve Schonfeld's Flexion Therapeutics, Inc. position peaked at $154K in Q2 2021.
  • 145 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.